Back to Search
Start Over
Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
- Source :
-
Annals of hepatology [Ann Hepatol] 2014 Sep-Oct; Vol. 13 (5), pp. 525-32. - Publication Year :
- 2014
-
Abstract
- Introduction: Hepatitis C (HCV) continues to be the leading indication for liver transplantation (LT). Sustained virological response (SVR) rates to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy for recurrent HCV in Genotype 1 (G1) LT recipients have been disappointing (30-40%). Experience with triple therapy using protease inhibitors (PI) boceprevir (BOC), telaprevir (TVR) in these patients has been limited.<br />Material and Methods: This national multicenter retrospective study included 76 patients (64 male, mean age 57 ± 6 years), treated for G1 HCV recurrence with either BOC (n = 41) or TVR (n = 35), who were non-responders or relapsers (n = 54), treatment naïve (n = 22) or had fibrosing cholestatic HCV (n = 3). 53 patients were on cyclosporine, 22 on tacrolimus and one patient on prednisone alone.<br />Results: On treatment virologic response was observed in 84% (64/76), 83% in BOC and 85% in TVR group. A higher week 4 response after starting triple therapy (RVR) was noted in TVR group 25/35 (81%) as compared to BOC group 26/41 (63%); p value = 0.02. The end of treatment response was 78% and 75% in BOC and TVR group, respectively. SVR 12 weeks after treatment discontinuation was observed in 59.5% (22/37); 58.3% in the BOC group and 61.5% in TVR group. Treatment was discontinued early in 23 patients (serious adverse effects n = 19, treatment failure n = 4). Infections occurred in 5 patients with 2 deaths (all in BOC). Anemia was the most common side effect (n = 55, 72%) requiring erythropoietin and RBV dose reduction. In the BOC group, cyclosporine dose reduction was 2.2 ± 1.0 fold and 8.6 ± 2.4 fold with tacrolimus. In TVR group, dose reduction was 3.0 ± 1.4 with cyclosporine and 12 ± 5.7 fold with tacrolimus.<br />Conclusions: PI-based triple therapy appears more effective in producing HCV-RNA clearance than dual therapy. Tolerability is a serious issue and drug-drug interactions are manageable with close monitoring.
- Subjects :
- Antiviral Agents adverse effects
Canada
Carrier Proteins antagonists & inhibitors
Carrier Proteins metabolism
Drug Interactions
Drug Therapy, Combination
End Stage Liver Disease virology
Female
Hepacivirus enzymology
Hepacivirus genetics
Hepatitis C, Chronic complications
Hepatitis C, Chronic diagnosis
Humans
Immunosuppressive Agents therapeutic use
Intracellular Signaling Peptides and Proteins
Male
Middle Aged
Oligopeptides adverse effects
Proline adverse effects
Proline therapeutic use
Protease Inhibitors adverse effects
RNA, Viral blood
Recurrence
Retrospective Studies
Time Factors
Treatment Outcome
Viral Load
Viral Nonstructural Proteins antagonists & inhibitors
Viral Nonstructural Proteins metabolism
Antiviral Agents therapeutic use
End Stage Liver Disease surgery
Hepacivirus drug effects
Hepatitis C, Chronic drug therapy
Liver Transplantation adverse effects
Oligopeptides therapeutic use
Proline analogs & derivatives
Protease Inhibitors therapeutic use
Virus Activation drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1665-2681
- Volume :
- 13
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Annals of hepatology
- Publication Type :
- Academic Journal
- Accession number :
- 25152985